Paul Hopper, an Australian bio-entrepreneur, looking to access public markets to help develop the PTX-100 & PTX-200 assets, helped coordinate sequential reverse takeovers wherein Virax first acquired Pathway Oncology (deal announced 17 March 2014,[1] completed 30 May 2014[2]) and then AKTivate Therapeutics (deal announced 17 October 2014,[3] completed 11 December 2014[4]).
This enzyme, by post translationally modifying the small GTPase Rho with isoprenoid lipids, plays a role in malignant transformation of cells and the inhibition of apoptosis.
[9] OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
The targeting ligand can then be administered and titrated separately to the CAR-T cells thereby creating on-demand and controllable T-cell activity post infusion.
This separation of the ligand dosing provides potential safety advantages through increased control of the resultant CAR activation throughout the therapy, as well as ability to target multiple antigens, either simultaneously or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.
[17] CellPryme-A, developed by Prescient in partnership with Peter Mac, was announced in September 2022 as an adjuvant / neoadjuvant therapy designed to be administered intravenously to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment.